· 3 min read
illuminem summarises for you the essential news of the day. Read the full piece on The Washington Post or enjoy below:
🗞️ Driving the news: A new AI-powered therapy known as adaptive deep brain stimulation (DBS) has significantly improved motor symptoms and quality of life for some Parkinson’s patients
• Recently approved by the FDA, the system adjusts brain stimulation in real time, responding to individual brain activity to better manage symptoms like tremors and dyskinesia
• Early results from clinical trials show reduced medication use and fewer side effects among participants
🔭 The context: Conventional DBS, used since 1997, delivers constant electrical stimulation, but adaptive DBS fine-tunes this therapy based on real-time brain signals using AI algorithms
• It targets abnormal neural patterns, or “oscillopathy,” that disrupt normal brain function in Parkinson’s
• Though not suitable for all patients, this evolving technology offers an advanced, non-pharmaceutical option for managing the disease
🌍 Why it matters for the planet: This AI-enhanced treatment reduces reliance on medication, which can come with high manufacturing footprints and adverse health impacts
• It also demonstrates the positive intersection of digital innovation and healthcare sustainability by offering more personalised, efficient treatment
• Advancements like these may inspire broader use of AI in precision medicine with less environmental burden
⏭️ What's next: Further clinical trials will refine when and where to stimulate the brain using adaptive DBS, guided by more sophisticated AI models
• Researchers hope to enhance targeting and response for even better outcomes
• Although the therapy won’t benefit all patients, its success could expand AI’s role in treating other neurological conditions
💬 One quote: “It’s not a cure or miracle, but it’s definitely a game changer... The tremor’s gone, dyskinesia is gone, and I don’t have that brain fog that I used to have,” — Keith Krehbiel, adaptive DBS participant
📈 One stat: In a recent trial, 98% of participants chose to stay on adaptive DBS after the initial 30-day period
See here detailed sustainability performance of companies like Medtronic, AbbVie, and Siemens Healthineers
Click for more news covering the latest on wellbeing and corporate governance
